Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years
| Autor: | Donald Shaw, R. H. T. Edwards, R. Hutcheon, P. Foy, M E Wallymahmed, Ian A. MacFarlane |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Endocrinology Diabetes and Metabolism Hospital Anxiety and Depression Scale Placebo Growth hormone deficiency law.invention Endocrinology Double-Blind Method Randomized controlled trial Quality of life law Internal medicine Health Status Indicators Humans Medicine Muscle Weakness business.industry Muscle weakness medicine.disease Nottingham Health Profile Growth Hormone Body Composition Quality of Life Lean body mass Female medicine.symptom business Follow-Up Studies |
| Zdroj: | Clinical Endocrinology. 47:439-446 |
| ISSN: | 0300-0664 |
| DOI: | 10.1046/j.1365-2265.1997.2801076.x |
| Popis: | OBJECTIVE Adults with GH deficiency complain frequently of low energy levels, emotional lability and mental fatigue resulting in a low perceived quality of life (QOL). Body composition is altered with increased fat mass and decreased lean body mass and muscle strength is reduced. The aims of this study were to determine the effects of replacement GH treatment on: (a) body composition and muscle strength and (b) QOL, using specifically selected and adapted measures. DESIGN A 12-month study (double-blind placebo-controlled for the first 6 months and open for the second 6 months) of GH replacement injections (0.125 iu/kg/week for the first month and 0.25 iu/kg/week for the following 5 months of each study period) in GH deficient adults on QOL, body composition and muscle strength. This was followed by an open study of a further 12 months' GH treatment assessing QOL and muscle strength. Finally, QOL was assessed after up to 3 years of GH replacement treatment. PATIENTS Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)). Nineteen patients then opted to continue GH treatment. Of these, 13 patients were available for assessment after a further 12 months' and 24 months' treatment. MEASUREMENTS Health-related QOL was assessed using 2 specifically adapted scales for adults with GH deficiency: the Life Fulfilment Scale and the Impact Scale. In addition 4 other self-rating questionnaires were used: Nottingham Health Profile, Hospital Anxiety and Depression Scale, Self Esteem Scale and Mental Fatigue Scale. Body composition was assessed by DEXA and quadriceps muscle strength by measuring maximum voluntary contractions. RESULTS In the initial 12 months' placebo-controlled study perceived energy levels increased after 6 and 12 months of GH treatment (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text